Table 3.
Demographics of Patients with CNV and Controls
| Eyes with CNV | |||||||
|---|---|---|---|---|---|---|---|
| PNV (n = 25) | PCV (n = 23) | Drusen-Associated nAMD (n = 24) | P * | Total CNV (N = 72) | Controls (n = 33) | P † | |
| Age (y), mean ± SD | 70.8 ± 9.4 | 72.6 ± 7.7 | 76.7 ± 8.6 | 0.054 | 73.5 ± 8.9 | 72.3 ± 6.3 | 0.17 |
| Sex, female, n (%) | 4 (16.0) | 6 (26.1) | 11 (45.8) | 0.066 | 21 (29.1) | 17 (51.5) | 0.028 |
| Complete PVD, n (%) | 12 (48.0) | 13 (56.5) | 11 (45.8) | 0.95 | 39 (54.2) | 20 (60.6) | 0.54 |
| Spherical equivalent (D), median (IQR) | 0.38 (–1.31 to 1.44) | 0 (–1.38 to 0.75) | –0.25 (–1.66 to 1.50) | 0.79 | 0.06 (–1.37 to 1.47) | –0.25 (–1.87 to 0.25) | 0.20 |
| CRT (µm), median (IQR) | 302 (221–441) | 414 (285–482) | 392 (348–572) | 0.029 | 379 (284–480) | — | — |
| SFCT (µm), median (IQR) | 340 (256–401) | 285 (226–353) | 210 (146–258) | 0.003 | 274 (204–351) | — | — |
| GLD (µm), median (IQR) | 3.5 (2.7–4.7) | 3.9 (3.5–5.0) | 4.9 (3.2–6.4) | 0.13 | 4.0 (2.9–5.2) | — | — |
| CNV size (mm2), median (IQR) | 1.4 (0.6–4.2) | 1.1 (0.7–2.5) | 2.2 (1.2–4.7) | 0.11 | 1.4 (0.8–3.5) | — | — |
| SRF, n (%) | 20 (80.0) | 21 (91.3) | 17 (70.8) | 0.18 | 58 (80.5) | — | — |
| IRF, n (%) | 1 (4.0) | 2 (8.7) | 8 (33.3) | 0.011 | 11 (15.3) | — | — |
| Soft drusen, n (%) | 0 (0) | 0 (0) | 11 (45.8) | <0.001 | 11 (10.6) | — | — |
| Pigmentary abnormalities, n (%) | 21 (84.0) | 20 (86.9) | 21 (87.5) | 0.93 | 62 (59.1) | — | — |
GLD, greatest linear dimension; SRF, subretinal fluid; IRF, intraretinal fluid.
*
Kruskal–Wallis test among CNV subtypes.
†
Mann–Whitney U test between the eyes with CNV and controls.